mzacks2

Michele

Michele Zacks

Research Development Scientist
Applied Structural Discovery

Location: TEMPE

Contact Information
Michele.Zacks@asu.edu
(480) 727-6464

Education

Ph.D., Experimental Pathology: Molecular/Cellular Biology of Parasites, University of Texas Medical Branch, 2007

M.S., Population and International Health: Infectious Disease Epidemiology, Harvard School of Public Heath, 1995

B.A., Biology, Kalamazoo College, 1989

Bio

Michele Zacks is a research development professional specializing in biomedical and life sciences grants? and for many years focused on international public health research. She has >20 years of experience working with clinical (medical and veterinary) and basic science researchers in teaching hospitals, biotech, and pharma in North and South America. She has worked in laboratories focused on cancer immunotherapy, parasitology, and virology in roles that encompassed bench work, scientific writing of manuscripts and grant/contract proposals, project management, study design, and data management, analysis, and presentation, including leadership of federal and industry site visits. In 2009, she began full time grant work at the Texas Heart Institute, across the spectrum of basic and applied cardiovascular disease research, including nanotechnology, imaging, drug development, and surgical/catheter engineering innovations. She was a founding member of Research Development Services, an office established by University of Arizona?s senior vice president for research and subsequently established a grants office in the University of Arizona Cancer Center. She has provided strategic guidance on hundreds of grants, offering assistance in submission timeline development; editing, synergizing multi-author content, and writing major parts of clinical, translational, and basic science grant applications to federal and state agencies, non-profit foundations, as well as private biotechnology funders.

Successful awards to her faculty clientele, totaling >$36M in budget requests, have included multiple agencies and mechanisms across the biomedical/technology funding landscape:  NIH (NASA/CASIS UG3/UH3, NIEHS/EPA P50, BRAIN R24, NCI UH2/UH3, P30, P30 Supplements, NIBIB R21, NCI R41, and RO1 from NIGMS, NIMH, NIEHS, and NINDS), DoD (CDMRP: BCRP, PRMRP, PCRP), USDA (NIFA-AFRI), NSF (Early CAREER), and NASA as well as state / private funders (ABRC, CIRM, Mendez Foundation).